|Description||Rosonabant is a CB1 receptor antagonist/inverse agonist originated by Esteve. It is an appetite suppressant for the treatment of obesity. But development of the drug for clinical use was apparently halted shortly after the related CB1 antagonist rimonabant was discontinued.|
|Synonyms||E-6776; E 6776; E6776; Rosonabant; (R)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4,5-dihydro-1H-pyrazole-3-carboxamide|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Esteve|
LY 320135 is a selective CB1 receptor antagonist.
AM 1172, an AEA analogue, has been found to be an anandamide uptake inhibitor as well as a cannabinoid receptor partial agonist.
Iodopravadoline, also known as AM630, is an inverse agonist at the human cannabinoid CB1 receptor. Iodopravadoline has been found to attenuate the ability of a ...
Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist(Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively).
JWH 133 is a synthetic cannabinoid and acts as a potent CB2 selective agonist with Ki value of 3.4 nM. It is used to synthesize CB2-selective cannabinoid recept...
Leelamine, a diterpene molecule, has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. Leelamine is also a PDK(p...
AM 6545 has been found to be a CB1 antagonist and could probably be used as an appetite suppressant.
COR 170 has been found to be an inverse agonist of CB2 receptors and could be used in studies for CB1 and CB2 receptor affinity.